Publication
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerGastrointestinal Stromal Tumorcivic_curation1.00
- drugRegorafenib Anhydrouscivic_curation1.00
- geneKITcivic_curation1.00
- variantKIT Exon 11 Mutationcivic_curation1.00
- variantKIT Exon 9 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23177515
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KIT Exon 11 Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID4599This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal str… (full text at CIViC) PMID 23177515 · Demetri et al., 2013 · Open in CIViC | civic |
| KIT Exon 9 Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID4628This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal str… (full text at CIViC) PMID 23177515 · Demetri et al., 2013 · Open in CIViC | civic |
| KIT Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID11283In this phase III, randomized, placebo-controlled trial, 240 patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rand… (full text at CIViC) PMID 23177515 · Demetri et al., 2013 · Open in CIViC | civic |
| PDGFRA Mutation1 | ||||||||
| Regorafenib Anhydrous | Gastrointestinal Stromal Tumor | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID11332In this phase III trial, 240 patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomized in 2:1 to receive either … (full text at CIViC) PMID 23177515 · Demetri et al., 2013 · Open in CIViC | civic |